- Report
- June 2025
- 150 Pages
Global
From €2369EUR$2,699USD£2,061GBP
- Report
- May 2024
- 137 Pages
Global
From €3510EUR$3,999USD£3,054GBP
Nonacog Alfa is a type of hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of factor VIII, a protein that helps the body form clots. Nonacog Alfa is used to replace the missing factor VIII in patients with hemophilia A, allowing them to form clots and stop bleeding. It is administered intravenously or subcutaneously, depending on the patient's needs.
Nonacog Alfa is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is currently marketed by several companies, including Novo Nordisk, Pfizer, and Biogen. Other companies, such as Shire, Bayer, and CSL Behring, also produce similar drugs for the treatment of hemophilia A. Show Less Read more